United-Guardian, Inc. (UG) Earnings Call Transcripts

United-Guardian, Inc.'s Latest Earnings Call - May 13, 2026

In the Q1 2026 earnings call for United-Guardian, Inc., management reported a rebound in net sales driven by higher pharmaceutical and cosmetic ingredient sales. Revenue for the quarter was $10.5 million, reflecting a positive shift from the previous year's $8.9 million. The company highlighted a strategic focus on expanding its pharmaceutical business, particularly with Renacidin, which is gaining traction due to improved formulary access. Management maintained its guidance for continued growth in the pharmaceutical segment, signaling optimism for the remainder of the fiscal year.

Reported metrics

Guidance from management

Management maintained its guidance for growth in the pharmaceutical segment, particularly with Renacidin, and indicated optimism for continued sales recovery in cosmetic ingredients.

What management said

Okay. Good morning. I'm Donna Vigilante, President of United Guardian, and I hereby call to order the Annual Meeting of the Stockholders of United Guardian, Inc., which is being held by video conference this 13th day of May 2026. Andrea Young, Secretary of the corporation, is present and pursuant to the bylaws of the corporation will act as Secretary of the meeting.

Good morning. I present a copy of the notice of this meeting, which has been sent to each stockholder of record together with proof of mailing of such notice. I ask that this notice and the affidavit of mailing be filed on the records of the corporation.

What analysts pressed on

Analysts expressed concerns about the executive compensation structure, particularly regarding reduced bonuses, and the challenges of entering international markets. There were also inquiries about the affordability of Renacidin for patients, highlighting potential barriers to sales growth.

Main topics on the call

• Revenue Growth — United-Guardian reported Q1 2026 net sales of $10.5 million, up from $8.9 million in Q1 2025, indicating a strong recovery. Management noted, "We are seeing an increase in pharmaceuticals, which is part of our efforts th...
• Pharmaceutical Business Expansion — The company has signed new distribution agreements to enhance its pharmaceutical offerings. Donna Vigilante stated, "We are starting to see some real traction there where that is allowing us to reduce the barrier for HCP...
• Cosmetic Ingredients Recovery — Cosmetic ingredient sales showed signs of recovery, increasing to 30% of the product mix in Q1 2026 from 28% in Q1 2025. This rebound is crucial for overall revenue growth as it complements the pharmaceutical segment.
• Strategic Goals — Management is focused on growth initiatives, including product innovation and expanding distributor partnerships. They are monitoring growth goals set for cosmetic ingredient distributors, indicating a proactive approach...

Read the full United-Guardian, Inc. transcript (May 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 United-Guardian, Inc. earnings call transcripts on record, spanning August 26, 2022 to May 13, 2026. Based on this history, United-Guardian, Inc. reports annually. The most recent call on file is dated May 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

UG

Exchange

NasdaqGM

Country

US

Sector

Consumer Staples

Industry

Personal Care Products

Calls on record

5

First call

August 26, 2022

Most recent

May 13, 2026

Reporting cadence

annually